Gilead Sciences (GILD) delivered a net profit margin of 27.9%, a sharp turnaround from just 0.4% a year ago, with earnings growth skyrocketing 6336.5% year over year. Looking ahead, management expects earnings to rise by 9.08% annually and revenue to grow at 4.5% per year, pointing to continued but more tempered expansion. Investors are weighing these strong headline results against prospects for steady future growth and value, especially with the company’s share price sitting below one major estimate of its fair value.
See our full analysis for Gilead Sciences.
The next step is to see how this latest batch of results stacks up against the narratives that investors and analysts have built around Gilead. Let’s dive into where the numbers confirm the story, and where they may spark new debate.
See what the community is saying about Gilead Sciences
NasdaqGS:GILD Earnings & Revenue History as at Nov 2025
Operating profitability surged, with Gilead delivering a net profit margin of 27.9% compared to just 0.4% the year before. This marks an improvement of more than 27 percentage points and is a sign the business is capturing more profit from every dollar of sales now.
The bullish narrative leans heavily on future margin expansion and product launches, but this dramatic rise in profitability is already reshaping the outlook:
Bulls highlight that projected margins are expected to rise even further. Bullish analysts see profit margins climbing from 20.8% today to 32.0% in three years, arguing that a strong R&D engine and new therapies like lenacapavir and Trodelvy will help maintain high margins.
However, the current margin outperformance beats even these optimistic assumptions. This suggests Gilead’s operational improvements and cost controls are already ahead of track, not just a future hope.
Valuation metrics show Gilead trading at a Price-to-Earnings (PE) ratio of 18.3x, slightly above the US Biotech industry average of 17.4x but substantially below peers’ 43.1x. This creates a tension between being relatively affordable next to direct competitors but still at a premium versus the broader sector.
Bulls argue Gilead is undervalued for its potential, but some key market checks are worth noting:
The share price ($119.79) sits well below the DCF fair value of $276.55, fueling bullish claims that there is major upside if the company’s earnings trajectory holds.
However, current analyst price targets cluster closer to $129.31, so the discount to modeled fair value is large, but the gap versus Wall Street’s expectations is modest. This raises the bar for a true rerating in the near term.
Story continues
Dividend attractiveness stands out, with Gilead recognized for strong cash flow supporting shareholder returns. However, the EDGAR summary reports that the financial position is “not indicated as strong” and calls for ongoing monitoring.
The consensus narrative captures this push-pull between reward and risk:
Consensus analysts credit disciplined expense management and share buybacks for supporting margin gains, but warn that Gilead’s heavy reliance on HIV therapies exposes its earnings and valuation to risk from future patent cliffs and new competition.
The relatively slow forecasted annual earnings growth rate of 9.08% and revenue growth of 4.5% per year point to steady but not explosive expansion. This leaves the company in a position where future pipeline success will be watched closely.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Gilead Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
Got your own take on these figures? Take a couple of minutes to share what you see and shape your own investment narrative. Do it your way
A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
Despite much-improved margins and growth, Gilead’s financial position still raises concerns as it is considered “not indicated as strong,” with heavy dependence on key therapies.
For investors seeking more robust financial health, use solid balance sheet and fundamentals stocks screener (1984 results) to uncover companies with stronger balance sheets and resilience through changing market conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GILD.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com